The U.S. Postal Service says medical marijuana remains nonmailable while it reviews the effects of federal rescheduling. That position, reported November 18 by Marijuana Moment, follows the announcement of a Georgia medical-cannabis shipping program. For patients, the immediate issue is the gap between a new delivery service’s plans and the postal agency’s stated rules.
A state’s permission to arrange medical cannabis delivery does not itself establish that USPS will accept the package. The current dispute concerns the carrier and federal mailability requirements, alongside state patient eligibility. It should not be read as a nationwide invitation for patients to send cannabis to one another.
What the Postal Service told reporters
Tom Angell’s reporting for Marijuana Moment attributes the statement to USPS senior public relations representative Felicia Lott. She said the agency and the Postal Inspection Service are reviewing medical marijuana’s mailability after its reclassification. She also said a future change would place it within the rules for prescription drugs containing controlled substances.
The outlet reported that USPS did not immediately provide a timetable for reaching a decision or explain where a decision would be announced. Georgia regulator Andrew Turnage disputed the agency’s interpretation in comments to the same outlet. Those are attributed positions in an unresolved policy disagreement, rather than evidence that the review has already produced a new rule.
That absence of a published decision matters. “Under review” describes work in progress. It does not tell a patient that a carrier has approved an individual shipment, and it does not establish that a state operator’s proposed method has been accepted by the Postal Service.
Why the Georgia announcement drew attention
In a November 17 company release, Botanical Sciences and Edibles.com announced a Georgia shipping platform for registered medical patients. The companies described a separate registry-verified ordering system with identity checks and delivery safeguards. They said the initial service would reach selected Botanical Sciences patients before expanding.
The release connects the launch to Georgia’s September 30 adoption of a medical-cannabis delivery rule. Its language describes what the companies intend to offer under the state framework. It is not a Postal Service authorization, and its claimed national first has not been independently established here.
The distinction is useful even outside Georgia. A delivery announcement can explain who may order, which products are offered and how the business plans to verify recipients. Whether a chosen carrier may transport those products is a further question. A tracking number or signature requirement records delivery activity; it does not independently establish that the contents are mailable.
What the published postal framework requires
USPS Publication 52, section 453, places responsibility on mailers to comply with postal regulations and applicable federal, state and local laws. It says mailing a controlled substance is unlawful when its distribution is unlawful. Controlled substances do not become ordinary parcels simply because the mailing stays within one state.
The section lists limited conditions for domestic mailing, including qualifying DEA-registered or exempt parties, approved mail-back programs and authorized dispensers sending mailable prescription medicines. These are defined channels with conditions, not a general exception for anyone holding a medical cannabis card.
The framework also treats hemp-based products separately, subject to legal compliance. That distinction makes product classification important: a seller’s use of “hemp,” “medical” or “CBD” in marketing cannot replace the applicable legal test. Patients should not infer that one kind of cannabinoid shipment proves every other kind is permitted.
What patients should ask before relying on shipping
A useful starting point is to ask the licensed provider which delivery method it currently offers and what authority supports that method. Ask whether the service is operating now, whether the patient’s address is eligible and how identity will be checked. Those details are especially important when public statements from the provider and the carrier do not align.
Patients should also distinguish commercial delivery by an authorized provider from personally mailing products to a friend, relative or another patient. The Georgia announcement does not establish permission for personal redistribution. Nor does the Postal Service’s review promise that a future change will cover every medical product, sender or recipient.
For now, the meaningful next development would be an official postal decision or updated published guidance, followed by a clear explanation from the state regulator and the service provider. A company announcement and an agency review are separate milestones. Until those positions are reconciled, patients should confirm the current delivery arrangements with their licensed provider rather than treat an announced shipping model as settled postal policy.
A review can change future policy, but it cannot supply an effective date that has not been announced.
Illustrative parcel stock photograph; not USPS mail, a cannabis shipment or the Georgia service. Photo: Liza Summer / Pexels.